Clinical Trials Directory

Trials / Completed

CompletedNCT02638545

Hemodynamic Effects of Dexmedetomidine in Septic Shock

Effects of Dexmedetomidine on Pressor Response to Norepinephrine in Patients With Septic Shock

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
37 (actual)
Sponsor
University of Roma La Sapienza · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The current treatment regimen of patients with septic shock requires a sufficient hemodynamic support aiming to preserve tissue oxygen requirements and perfusion. Therefore, aggressive fluid challenge and vasopressor agents play a pivotal role. To increase total peripheral resistance and preserve organ perfusion, a continuous infusion of catecholamines is often needed. Because sepsis is usually associated with adrenergic receptor and post-receptor abnormalities, the efficacy of such treatment regimens often gradually decreases over time, thereby complicating hemodynamic support. Experimental evidence suggest that α-2 agonists increase pressor responsiveness following lipopolysaccharide administration. This study will assess the effects of the sedation with dexmedetomidine (α-2 agonist) on norepinephrine requirements in patients with septic shock.

Detailed description

The present study was designed as a prospective study. All patients enrolled in the study will require norepinephrine to maintain MAP between 65 and 75 mmHg despite adequate volume resuscitation and will be sedated according to istitutional guidelines with propofol and remifentanyl. After 8 h had elapsed during stable hemodynamic conditions, an initial set of measurements will be obtained during the sedation with propofol and remifentanyl. This set of measurements will be considered as baseline. In the patients in which conventional sedation will be replaced by dexmedetomidine and remifentanyl, a second set of measurements will be obtained after 4 h had elapsed during stable conditions. A final set of mesurements will be obtained after another 8-h period in stable conditions after switcheing back again to propofol and remifentanyl, . During the observational period the dosage rate of norepinephrine will be adjusted to maintain the same threshold MAP of 65-75 mmHg All other medications were held constant.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineSedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl

Timeline

Start date
2015-09-01
Primary completion
2017-01-01
Completion
2017-02-01
First posted
2015-12-23
Last updated
2017-02-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02638545. Inclusion in this directory is not an endorsement.